1089758-61-1

Basic information

• Product Name: 1-[(5-bromo-2,3-dihydro-2,2-dimethyl-benzofuran-7-yl)-oxy]-3-[4-(3-trifluoromethyl-phenyl)-1,2,5,6-tetrahydro-pyridin-1-yl]-propane
• Synonyms: 1-[(5-bromo-2,3-dihydro-2,2-dimethyl-benzofuran-7-yl)-oxy]-3-[4-(3-trifluoromethyl-phenyl)-1,2,5,6-tetrahydro-pyridin-1-yl]-propane
• CAS NO: 1089758-61-1
• Molecular Weight: 510.394
• Mol File: 1089758-61-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-[(5-bromo-2,3-dihydro-2,2-dimethyl-benzofuran-7-yl)-oxy]-3-[4-(3-trifluoromethyl-phenyl)-1,2,5,6-tetrahydro-pyridin-1-yl]-propane(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[(5-bromo-2,3-dihydro-2,2-dimethyl-benzofuran-7-yl)-oxy]-3-[4-(3-trifluoromethyl-phenyl)-1,2,5,6-tetrahydro-pyridin-1-yl]-propane(1089758-61-1)
• EPA Substance Registry System: 1-[(5-bromo-2,3-dihydro-2,2-dimethyl-benzofuran-7-yl)-oxy]-3-[4-(3-trifluoromethyl-phenyl)-1,2,5,6-tetrahydro-pyridin-1-yl]-propane(1089758-61-1)

Safety Data

• Hazardous Substances Data: 1089758-61-1(Hazardous Substances Data)

Upstream product

• 250289-97-5 5-bromo-2,2-dimethyl-2,3-dihydrobenzofuran-7-ol 
• 1089210-22-9 5-bromo-2,3-dihydro-2,2-dimethyl-7-(3-chloro-propoxy)-benzofuran 
• 1683-23-4 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridinium chloride 

Relevant articles and documents

NEW BENZOFURAN DERIVATIVES AS SELECTIVE 5HT7 RECEPTOR INHIBITORS AND PROCESS FOR THEIR PREPARATION

The present invention relates to new selective 5HT7 receptor binding benzofuran derivatives of general formula (I), wherein X represents a halogen atom or SO2NR1R2 group, wherein R1 and R2 represent, independently, a hydrogen atom, C1-6 alkyl group, C3-6 cycloalkyl group, phenyl group substituted with one or more halogen atom(s) or 1,7.7-trimethyl-bicyclo[2,2,1]hept-2-yl group, Y represents C2-6 alkylene group, optionally substituted with hydroxy group, A represents carbon atom, nitrogen atom or CH group, B represents CH or CH2 group, Q represents C1-4 alkyl group, a phenyl group optionally substituted with one or more halogen atom(s), C1-4 alkoxy group or trifluoromethyl group; phenylamino group substituted with a halogen atom or trifluoromethyl group; pyridine heterocycle; benzisoxazole or benzisothiazole heterocycle, optionally substituted with a halogen atom; benzimidazole or benzimidazolone heterocycle, optionally substituted with a halogen atom or trifluoromethyl group on the benzene ring, or optionally substituted on one of the N atoms with an C1-4 alkyl group; benzodioxane heterocycle, optionally substituted with a halogen atom on the benzene ring; pyridazinone heterocycle substituted with a halogen atom; dibenzothiazepine heterocycle or Q together with groups A and B represents a thiophene ring and their pharmaceutically suitable acid addition salts, with the proviso that if Y represents 2-hydroxy propylene group, A represents a carbon atom, B represents CH group, and Q represents 3-trifluoro-methyl-phenyl group, then X does not represent bromo atom. The invention extends to the process for producing said compounds, to pharmaceutical compositions containing said compounds and to their use in treatment and/or prevention of disorders of the central nervous system and cardiovascular system.